vadimezan has been researched along with B16 Melanoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banciu, M; Licarete, E; Luput, L; Mot, AC; Patras, L; Porfire, A; Rakosy-Tican, E; Rauca, VF; Sesarman, A; Toma, VA | 1 |
| Cichoń, T; Jarosz-Biej, M; Kułach, N; Pilny, E; Poczkaj, A; Smolarczyk, R; Szala, S | 1 |
| Banciu, M; Bulzu, P; Licarete, E; Luput, L; Patras, L; Rakosy-Tican, E; Rauca, VF; Sesarman, A | 1 |
| Cho, MY; Choi, I; Hong, KS; Korm, S; Lee, H; Lee, JY; Lim, YT; Park, C; Seth, A | 1 |
4 other study(ies) available for vadimezan and B16 Melanoma
| Article | Year |
|---|---|
Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Disease Progression; Liposomes; Macrophages; Male; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Oxidative Stress; Simvastatin; Skin Neoplasms; Tumor Microenvironment; Xanthones | 2021 |
Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Digoxin; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Macrophages; Melanoma; Melanoma, Experimental; Mice; Neovascularization, Pathologic; Xanthones; Xenograft Model Antitumor Assays | 2018 |
Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells.
Topics: Angiogenesis Inhibitors; Animals; Cell Communication; Cell Movement; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Macrophages; Melanoma, Experimental; Mice; Neoplasm Invasiveness; Neovascularization, Pathologic; Simvastatin; Tumor Microenvironment; Xanthones | 2018 |
Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.
Topics: Aminoquinolines; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Drug Delivery Systems; Imidazoles; Immunotherapy; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Nanoparticles; Toll-Like Receptor 7; Toll-Like Receptor 8; Xanthones | 2017 |